SightfileU.S. market data from official filings

Companies › AGMB

AGOMAB THERAPEUTICS NV (AGMB)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002020932 · EDGAR filings · Updated 2026-06-23

AGOMAB THERAPEUTICS NV (AGMB) has reported institutional ownership of 68.4%, with 32 institutional managers holding positions valued at $245.3M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
68.4%
Institutional managers
32
Reported 13F value
$245.3M
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, AGOMAB THERAPEUTICS NV has 32 institutional holders and institutional ownership of 68.4%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 1 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-04-23 (recurring since 2026-04-23) — source filing. The authoritative details are those stated in the filing itself.

Related companies

PALISADE BIO INC (PALI) · EIKON THERAPEUTICS INC (EIKN) · Immix Biopharma Inc (IMMX) · PROTARA THERAPEUTICS INC (TARA) · LYELL IMMUNOPHARMA INC (LYEL) · RXSIGHT INC (RXST)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-23.